Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncogenic signaling of MEK5-ERK5.
Hoang VT, Yan TJ, Cavanaugh JE, Flaherty PT, Beckman BS, Burow ME. Hoang VT, et al. Among authors: flaherty pt. Cancer Lett. 2017 Apr 28;392:51-59. doi: 10.1016/j.canlet.2017.01.034. Epub 2017 Jan 30. Cancer Lett. 2017. PMID: 28153789 Free PMC article. Review.
Structure activity relationships of anthranilic acid-based compounds on cellular and in vivo mitogen activated protein kinase-5 signaling pathways.
Chakrabarty S, Monlish DA, Gupta M, Wright TD, Hoang VT, Fedak M, Chopra I, Flaherty PT, Madura J, Mannepelli S, Burow ME, Cavanaugh JE. Chakrabarty S, et al. Among authors: flaherty pt. Bioorg Med Chem Lett. 2018 Jul 15;28(13):2294-2301. doi: 10.1016/j.bmcl.2018.05.029. Epub 2018 May 20. Bioorg Med Chem Lett. 2018. PMID: 29803729 No abstract available.
Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Wright TD, Raybuck C, Bhatt A, Monlish D, Chakrabarty S, Wendekier K, Gartland N, Gupta M, Burow ME, Flaherty PT, Cavanaugh JE. Wright TD, et al. Among authors: flaherty pt. J Cell Biochem. 2020 Feb;121(2):1156-1168. doi: 10.1002/jcb.29350. Epub 2019 Aug 28. J Cell Biochem. 2020. PMID: 31464004 Free PMC article.
ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer.
Hoang VT, Matossian MD, Ucar DA, Elliott S, La J, Wright MK, Burks HE, Perles A, Hossain F, King CT, Browning VE, Bursavich J, Fang F, Del Valle L, Bhatt AB, Cavanaugh JE, Flaherty PT, Anbalagan M, Rowan BG, Bratton MR, Nephew KP, Miele L, Collins-Burow BM, Martin EC, Burow ME. Hoang VT, et al. Among authors: flaherty pt. Front Oncol. 2020 Aug 3;10:1164. doi: 10.3389/fonc.2020.01164. eCollection 2020. Front Oncol. 2020. PMID: 32850332 Free PMC article.
Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
Hoang VT, Matossian MD, La J, Hoang K, Ucar DA, Elliott S, Burks HE, Wright TD, Patel S, Bhatt A, Phamduy T, Chrisey D, Buechlein A, Rusch DB, Nephew KP, Anbalagan M, Rowan B, Cavanaugh JE, Flaherty PT, Miele L, Collins-Burow BM, Burow ME. Hoang VT, et al. Among authors: flaherty pt. J Cell Biochem. 2021 Aug;122(8):835-850. doi: 10.1002/jcb.29916. Epub 2021 Apr 20. J Cell Biochem. 2021. PMID: 33876843
Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer.
Matossian MD, Hoang VT, Burks HE, La J, Elliott S, Brock C, Rusch DB, Buechlein A, Nephew KP, Bhatt A, Cavanaugh JE, Flaherty PT, Collins-Burow BM, Burow ME. Matossian MD, et al. Among authors: flaherty pt. Oncoscience. 2021 May 18;8:64-71. doi: 10.18632/oncoscience.535. eCollection 2021. Oncoscience. 2021. PMID: 34026925 Free PMC article.
28 results